Physician profile
Tinyee T Chang
NPI 1386861409
$17,331.53
in general payments reported to CMS, 2019-2025
33 companies · $2,439 in 2025
The $2,439 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,057 · 2020: $1,489 · 2021: $2,123 · 2022: $3,156 · 2023: $3,212 · 2024: $2,855 · 2025: $2,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,028 · Education: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,027.76 |
| Education | $478.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,586.71 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Regeneron Healthcare Solutions, INC. | $2,329.21 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,796.10 | 2019-2025 | |
| Janssen Biotech, INC. | $1,400.20 | 2019-2025 | Tremfya, Stelara, Remicade |
| Lilly USA, LLC | $1,203.66 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $1,007.69 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $888.80 | 2019-2025 | |
| Amgen INC. | $783.79 | 2019-2025 | Otezla |
| Sun Pharmaceutical Industries INC. | $622.07 | 2019-2024 | |
| Merz North America, INC. | $583.54 | 2019-2023 | Xeomin |
| Novartis Pharmaceuticals Corporation | $495.44 | 2019-2025 | |
| Incyte Corporation | $480.58 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $368.66 | 2019-2023 | Adbry |
| Dermavant Sciences, INC. | $202.84 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $172.64 | 2019-2025 | Jublia, Siliq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $165.90 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $162.38 | 2023-2024 | Sotyktu |
| Dermira, INC. | $138.82 | 2019-2021 | |
| Organon LLC | $113.97 | 2024-2025 | Vtama, Hadlima, Nexplanon |
| Arcutis Biotherapeutics, INC. | $112.17 | 2023-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $103.91 | 2021-2025 | |
| Phadia US INC. | $99.28 | 2021-2025 | Immunocap |
| Regeneron Pharmaceuticals, INC. | $97.10 | 2023 | Dupixent |
| Strata Skin Sciences, INC. | $73.16 | 2019-2023 | Xtrac |
| Dusa Pharmaceuticals, INC. | $69.27 | 2019 | |
| Merck Sharp & Dohme LLC | $58.18 | 2019 | |
| Celgene Corporation | $45.32 | 2019 | |
| Prugen, INC. Pharmaceuticals | $42.09 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $40.46 | 2019 | |
| Paratek Pharmaceuticals, INC. | $30.45 | 2024 | Nuzyra |
| Sanofi US Services INC. | $27.08 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $15.55 | 2019 | |
| Botanix Sb INC | $14.51 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tinyee Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.